Cargando…

Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort

SIMPLE SUMMARY: Active surveillance (AS) is a standard option for low-risk prostate cancer patients wishing to preserve their quality of life by avoiding or delaying radical treatment side effects. We investigated the consequences of postponing radical prostatectomy (RP) according to stringent or mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Marenghi, Cristina, Qiu, Zhuyu, Helleman, Jozien, Nieboer, Daan, Rubio-Briones, Josè, Carroll, Peter R., Lee, Lui Shiong, Valdagni, Riccardo, Boutros, Paul C., Nicolai, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332009/
https://www.ncbi.nlm.nih.gov/pubmed/35892817
http://dx.doi.org/10.3390/cancers14153558
_version_ 1784758543692333056
author Marenghi, Cristina
Qiu, Zhuyu
Helleman, Jozien
Nieboer, Daan
Rubio-Briones, Josè
Carroll, Peter R.
Lee, Lui Shiong
Valdagni, Riccardo
Boutros, Paul C.
Nicolai, Nicola
author_facet Marenghi, Cristina
Qiu, Zhuyu
Helleman, Jozien
Nieboer, Daan
Rubio-Briones, Josè
Carroll, Peter R.
Lee, Lui Shiong
Valdagni, Riccardo
Boutros, Paul C.
Nicolai, Nicola
author_sort Marenghi, Cristina
collection PubMed
description SIMPLE SUMMARY: Active surveillance (AS) is a standard option for low-risk prostate cancer patients wishing to preserve their quality of life by avoiding or delaying radical treatment side effects. We investigated the consequences of postponing radical prostatectomy (RP) according to stringent or more expansive criteria at inclusion in active surveillance. Features at radical prostatectomy of men withdrawn from AS showed that most of them still have favorable pathology. Frequency of unfavorable pathology was associated with wider entry criteria, PSA density (PSAD) and age, and time spent in active surveillance. Nonetheless, they are restricted to local tumor extension and positive surgical margins, but do not include tumor grade or lymph node involvement. The prognostic implications of these findings remain uncertain, and a longer follow-up is needed. ABSTRACT: Background: Little is known about the consequences of delaying radical prostatectomy (RP) after Active Surveillance (AS) according to stringent or wider entry criteria. We investigated the association between inclusion criteria and rates, and timing of adverse pathological findings (APFs) among patients in GAP3 cohorts. Methods: APFs (GG ≥ 3, pT ≥ 3, pN > 0 and positive surgical margins [R1]) were accounted for in very low-risk (VLR: grade group [GG] 1, cT1, positive cores < 3, PSA < 10 ng/mL, PSA density [PSAD] < 0.15 ng/mL/cm(3)) and low-risk (LR: GG1, cT1-2, PSA ≤ 10 ng/mL) patients undergoing subsequent RP. The Kaplan–Meier method and log–rank test analyzed APF-free survival. Stratified mixed effects models analyzed association. Results: Out of 21,169 patients on AS, 1742 (VLR: 721; LR: 1021) underwent delayed RP. Most (60.8%) did not have APFs. APFs occurred more frequently (44.6% vs. 31.7%; OR 1.54, p < 0.001) and earlier (median time: 40.3 vs. 62.6 months; p < 0.001) in LR patients, and consisted of pT ≥ 3 (OR 1.47, p = 0.013) or R1 (OR 1.80, p < 0.001), but not of GG ≥ 3 or node involvement. Age (OR 1.05, p < 0.001), PSAD (OR 23.21, p = 0.003), and number of positive cores (OR 1.16, p = 0.004) were independently associated with APFs. Conclusions: AS stands as a safe option for low-risk patients, and most do not have APFs at surgery. Wider entry criteria are associated with pT3 and R1. The prognostic implications remain uncertain.
format Online
Article
Text
id pubmed-9332009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93320092022-07-29 Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort Marenghi, Cristina Qiu, Zhuyu Helleman, Jozien Nieboer, Daan Rubio-Briones, Josè Carroll, Peter R. Lee, Lui Shiong Valdagni, Riccardo Boutros, Paul C. Nicolai, Nicola Cancers (Basel) Article SIMPLE SUMMARY: Active surveillance (AS) is a standard option for low-risk prostate cancer patients wishing to preserve their quality of life by avoiding or delaying radical treatment side effects. We investigated the consequences of postponing radical prostatectomy (RP) according to stringent or more expansive criteria at inclusion in active surveillance. Features at radical prostatectomy of men withdrawn from AS showed that most of them still have favorable pathology. Frequency of unfavorable pathology was associated with wider entry criteria, PSA density (PSAD) and age, and time spent in active surveillance. Nonetheless, they are restricted to local tumor extension and positive surgical margins, but do not include tumor grade or lymph node involvement. The prognostic implications of these findings remain uncertain, and a longer follow-up is needed. ABSTRACT: Background: Little is known about the consequences of delaying radical prostatectomy (RP) after Active Surveillance (AS) according to stringent or wider entry criteria. We investigated the association between inclusion criteria and rates, and timing of adverse pathological findings (APFs) among patients in GAP3 cohorts. Methods: APFs (GG ≥ 3, pT ≥ 3, pN > 0 and positive surgical margins [R1]) were accounted for in very low-risk (VLR: grade group [GG] 1, cT1, positive cores < 3, PSA < 10 ng/mL, PSA density [PSAD] < 0.15 ng/mL/cm(3)) and low-risk (LR: GG1, cT1-2, PSA ≤ 10 ng/mL) patients undergoing subsequent RP. The Kaplan–Meier method and log–rank test analyzed APF-free survival. Stratified mixed effects models analyzed association. Results: Out of 21,169 patients on AS, 1742 (VLR: 721; LR: 1021) underwent delayed RP. Most (60.8%) did not have APFs. APFs occurred more frequently (44.6% vs. 31.7%; OR 1.54, p < 0.001) and earlier (median time: 40.3 vs. 62.6 months; p < 0.001) in LR patients, and consisted of pT ≥ 3 (OR 1.47, p = 0.013) or R1 (OR 1.80, p < 0.001), but not of GG ≥ 3 or node involvement. Age (OR 1.05, p < 0.001), PSAD (OR 23.21, p = 0.003), and number of positive cores (OR 1.16, p = 0.004) were independently associated with APFs. Conclusions: AS stands as a safe option for low-risk patients, and most do not have APFs at surgery. Wider entry criteria are associated with pT3 and R1. The prognostic implications remain uncertain. MDPI 2022-07-22 /pmc/articles/PMC9332009/ /pubmed/35892817 http://dx.doi.org/10.3390/cancers14153558 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marenghi, Cristina
Qiu, Zhuyu
Helleman, Jozien
Nieboer, Daan
Rubio-Briones, Josè
Carroll, Peter R.
Lee, Lui Shiong
Valdagni, Riccardo
Boutros, Paul C.
Nicolai, Nicola
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title_full Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title_fullStr Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title_full_unstemmed Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title_short Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
title_sort adverse pathological findings at radical prostatectomy following active surveillance: results from the movember gap3 cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332009/
https://www.ncbi.nlm.nih.gov/pubmed/35892817
http://dx.doi.org/10.3390/cancers14153558
work_keys_str_mv AT marenghicristina adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT qiuzhuyu adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT hellemanjozien adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT nieboerdaan adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT rubiobrionesjose adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT carrollpeterr adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT leeluishiong adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT valdagniriccardo adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT boutrospaulc adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT nicolainicola adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort
AT adversepathologicalfindingsatradicalprostatectomyfollowingactivesurveillanceresultsfromthemovembergap3cohort